SenzaGen agrees to acquire UK's Alcyomics for initial SEK 28 million
Bitget2026/10/28 18:41- SenzaGen agreed to acquire 100% of UK non-animal immunotoxicology specialist Alcyomics for an initial GBP 2.12 million in cash.
- Two potential cash earn-outs are capped at GBP 0.83 million for performance milestones and GBP 1.05 million for net-debt reduction.
- Completion is expected around November 4, 2026, expanding the group's non-animal testing offering into preclinical drug development.
- Funding combines existing cash with SEK 25 million of convertible bonds issued to principal owner Eiffel Investment Group, carrying 5.5% annual interest.
- Alcyomics' revenue rose 46% to approximately GBP 1.49 million in fiscal 2025/2026, with an EBITDA margin of approximately 24%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-IIFL Finance rallies to a two-month high, boosted by Blackstone deal
The “outlier” in the AI capital expenditure frenzy: Apple (AAPL.US) keeps spending flat, accounting for less than 5% of sales
Apple continues to stand out among major tech peers, largely avoiding the aggressive wave of capital expenditure associated with artificial intelligence (AI) infrastructure.
Youth Employment Declines for 48 Consecutive Months: Behind the Semiconductor Boom, Young South Koreans Are Being Left Behind by the Times
In South Korea, the unemployment rate in October fell to a three-year low of 2.5%. However, the number of employed people decreased by 50,000, youth employment has declined for 48 consecutive months, and domestic demand remains weak.
Crypto prices
More
